Technology
Health
Biotechnology

Ardelyx

$3.35
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.07 (2.13%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Ardelyx and other stocks, options, ETFs, and crypto commission-free!

About

Ardelyx, Inc. Common Stock, also called Ardelyx, is a biopharmaceutical company, which engages in the research, development and commercialization of medicine for the treatment of renal diseases. Read More It focuses on the formulation of programs directed toward treating gastrointestinal and irritable bowel syndrome with constipations. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Fremont, CA.

Employees
86
Headquarters
Fremont, California
Founded
2007
Market Cap
205.05M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
408.52K
High Today
$3.45
Low Today
$3.20
Open Price
$3.21
Volume
107.02K
52 Week High
$5.90
52 Week Low
$1.60

Collections

Technology
Health
Biotechnology
Medical
Biopharmaceutical
Pharmaceutical
2014 IPO
US

News

Simply Wall StMar 21

What Did Ardelyx, Inc.’s (NASDAQ:ARDX) CEO Take Home Last Year?

Mike Raab has been the CEO of Ardelyx, Inc. (NASDAQ:ARDX) since 2009. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar size. After that, we will consider the growth in the business. And finally – as a second measure of performance – we will look at the returns shareholders have received over the last few years. This process should give us an idea about how appropriately the CEO is paid. Check out our latest analysis for Ardelyx How Does...

15
Guru FocusMar 6

Ardelyx Reports Fourth Quarter 2018 Financial Results and Recent Highlights

FREMONT, Calif., March 6, 2019 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing first-in-class medicines to improve treatment choices for people with cardiorenal diseases, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2018. "Over the last year, we made significant progress towards developing our lead product candidate, tenapanor, and executing on our plan to provide patients with this first-eve...

142
PR NewswireFeb 21

Ardelyx to Participate in Leerink Partners 8th Annual Global Healthcare Conference

About Ardelyx, Inc. Ardelyx is focused on enhancing the way people with cardiorenal diseases are treated by developing first-in-class medicines. Ardelyx's cardiorenal pipeline includes the Phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease (ESRD) who are on dialysis, and RDX013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. In addi...

45

Earnings

-$0.64
-$0.36
-$0.07
$0.21
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected May 7, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.